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Background: Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort
A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with
mTNBC.
Patients and methods: Eligible patients had centrally confirmed mTNBC, 1 systemic therapy for metastatic disease, prior
treatment with anthracycline and taxane in any disease setting, and progression on or after the most recent therapy. Patients
received pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years. Primary end points were objective response rate
in the total and PD-L1–positive populations, and safety. Secondary end points included duration of response, disease control
rate (percentage of patients with complete or partial response or stable disease for24 weeks), progression-free survival, and
overall survival.
Results: All enrolled patients (N¼ 170) were women, 61.8% had PD-L1–positive tumors, and 43.5% had received 3 previous
lines of therapy for metastatic disease. ORR (95% CI) was 5.3% (2.7–9.9) in the total and 5.7% (2.4–12.2) in the PD-L1–positive
populations. Disease control rate (95% CI) was 7.6% (4.4–12.7) and 9.5% (5.1–16.8), respectively. Median duration of response
was not reached in the total (range, 1.2þ–21.5þ) and in the PD-L1–positive (range, 6.3–21.5þ) populations. Median PFS was
2.0 months (95% CI, 1.9–2.0), and the 6-month rate was 14.9%. Median OS was 9.0 months (95% CI, 7.6–11.2), and the 6-month
rate was 69.1%. Treatment-related adverse events occurred in 103 (60.6%) patients, including 22 (12.9%) with grade 3 or 4 AEs.
There were no deaths due to AEs.
Conclusions: Pembrolizumab monotherapy demonstrated durable antitumor activity in a subset of patients with previously
treated mTNBC and had a manageable safety profile.
Clinical trial registration: ClinicalTrials.gov, NCT02447003
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Introduction
Treatment of metastatic triple-negative breast cancer TNBC
(mTNBC) is challenging and survival, despite standard of
care cytotoxic chemotherapy, is poor (median OS, 9–17 months)
[1, 2]. Only a limited subset of patients with germline BReast
CAncer gene (BRCA)-related TNBC benefit from poly (ADP-ri-
bose) polymerase (PARP) inhibitors, the only available targeted
therapy [3, 4]. Current therapies are frequently associated with
significant toxicity. The aggressive disease biology coupled with
the suboptimal treatment outcomes underscore the urgent need
for new therapies to effectively treat mTNBC.
The programmed death receptor 1 (PD-1) pathway is fre-
quently co-opted by tumors to evade an immune response [5].
Pembrolizumab is a high-affinity, highly selective, humanized
monoclonal IgG4-K antibody against PD-1 that provides dual lig-
and blockade of programmed death-ligand 1 (PD-L1) and 2 (PD-
L2). PD-L1 is not detected in normal breast tissue, but is
expressed in approximately half of all breast cancers, with expres-
sion generally higher in TNBC [6–8]. The phase Ib KEYNOTE-
012 study in patients with PD-L1–positive mTNBC (N¼ 27)
showed that pembrolizumab had manageable safety and durable
antitumor activity in a subset of patients [9]. The present study
examined the efficacy and safety of pembrolizumab monotherapy
in a large cohort of patients with previously treated mTNBC, re-
gardless of PD-L1 expression.
Methods
Study design and patients
KEYNOTE-086 (ClinicalTrials.gov, NCT02447003) was an international,
open-label, multicohort, phase II study of pembrolizumab monotherapy
in patients with mTNBC. Eligibility for cohort A was 1 prior systemic
treatment for metastatic disease, treatment with anthracycline and taxane
in the neoadjuvant, adjuvant, or metastatic setting, and documented dis-
ease progression on or after the most recent therapy. Men and women
were eligible for enrollment if they were aged 18 years, had centrally
confirmed TNBC [10], an Eastern Cooperative Oncology Group
(ECOG) performance status of 0 or 1, baseline lactate dehydrogenase
(LDH) levels <2.5x ULN, and measurable disease based on Response
Evaluation Criteria in Advanced Solid Tumors, version 1.1 (RECIST
v1.1) assessed by independent central radiology review. All patients were
required to provide tumor tissue from a newly obtained (within 56 days
of the first dose of study medication) core or excisional biopsy sample
(preferred) or archival tumor sample of a nonirradiated lesion for central
confirmation of TNBC status and determination of PD-L1 status.
Exclusion criteria included radiographically detectable central nervous
system metastases, regardless of symptomatology or previous treatment;
active autoimmune disease that required systemic treatment within the
previous 2 years; history of noninfectious pneumonitis or interstitial lung
disease; prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 or an-
other co-inhibitory T-cell receptor; an antineoplastic monoclonal anti-
body within the previous 4 weeks; chemotherapy, targeted small
molecule therapy, or radiation therapy within the previous 2 weeks; or
adverse events (AEs) from previous therapy that had not resolved to
grade1 or baseline.
All patients provided written, informed consent. The study protocol
was approved by the independent ethics committee or review board at
each participating institution. The study was conducted in accordance
with the Declaration of Helsinki and the International Conference on
Harmonization Guidelines for Good Clinical Practice.
Study treatment
Pembrolizumab 200 mg was administered intravenously over 30 min
every 3 weeks for up to 2 years. Treatment was discontinued upon disease
progression, intolerable toxicity, physician decision, or patient with-
drawal of consent. Clinically stable patients with radiologic evidence of
disease progression could continue treatment until radiologic progres-
sion was confirmed at the next imaging assessment4 weeks later.
Assessments
PD-L1 expression was assessed during screening at a central laboratory
(Q2 Solutions, Valencia, CA) using the PD-L1 IHC 22C3 pharmDx kit
(Agilent, Carpinteria, CA). The measure of expression was the combined
positive score (CPS), defined as the ratio of PD-L1–positive cells (tumor
cells, lymphocytes, and macrophages) out of the total number of tumor
cells 100. PD-L1 positivity was defined as CPS1 (previously reported
as, and equivalent to, CPS 1%). Tumor imaging was performed by
computed tomography (preferred) or magnetic resonance imaging at
baseline, and every 9 weeks thereafter through 12 months, then every
12 weeks.
Physical examination and laboratory tests were performed and vital
signs were assessed at baseline and regularly throughout study treatment.
AEs were monitored throughout treatment and for 30 days thereafter
(90 days for serious AEs) and graded according to the National Cancer
Institute Common Terminology Criteria for Adverse Events, version 4.0.
Statistical analysis
Primary and secondary efficacy end points were assessed by independent
central radiology review based on RECIST v1.1. Primary end points were
objective response rate [ORR; the proportion of patients with complete
response (CR) or partial response (PR)] in the total and PD-L1–positive
populations, and safety. Secondary end points, evaluated in the total
population and by PD-L1 status, included duration of response (the time
from initial radiologic evidence of CR or PR to disease progression or
death, whichever occurred first); disease control rate [DCR; the propor-
tion of patients with CR or PR or stable disease (SD) for24 weeks]; pro-
gression-free survival (PFS; the time from first dose of pembrolizumab to
disease progression or death, whichever occurred first); and overall sur-
vival (OS; the time from first dose of pembrolizumab to death). Efficacy
was assessed in all patients with measurable disease at baseline who
received 1 dose of pembrolizumab. Safety was assessed in all patients
who received1 dose of pembrolizumab.
For ORR, the point estimate 95% Agresti-Coull confidence interval
(CI) was provided based on normal approximation for the binomial dis-
tribution. Participants without response data were counted as nonres-
ponders. For DCR, similar estimation methods used for ORR were
applied. For duration of response, PFS, and OS, Kaplan–Meier curves,
median estimates, and survival at 6 and 12 months based on the Kaplan–
Meier curves (95% CI based on Greenwood’s formula) were provided, as
appropriate. Participants without efficacy evaluation or survival data
were censored at day 1. Summary statistics were provided for baseline
demographics, disease characteristics, and AEs. The target sample size
was approximately 160 patients. The current analysis was based on the
data cut-off date of 10 November 2017.
Results
Patients
Of 388 patients screened, 170 patients, including 105 (61.8%)
with PD-L1–positive tumors, were allocated between 17 July
2015 and 29 January 2016 at 48 sites in 13 countries (supplemen-
tary Table S1, available at Annals of Oncology online). The most
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common reasons for nonenrollment were the presence of radio-
graphically detectable central nervous system metastases [N¼ 64
(29.4%)] and inadequate organ function [N¼ 55 (25.2%)]. All
enrolled patients received 1 dose of pembrolizumab. After a
median follow-up of 9.6 months (range, 0.1–25.7), 165 (97.1%)
patients discontinued pembrolizumab, most commonly for dis-
ease progression [N¼ 153 (90.0%)] (supplementary Figure S1,
available at Annals of Oncology online). Median duration of ex-
posure to pembrolizumab was 57 days (range, 1–740), and the
median number of pembrolizumab doses was 3 (range, 1–35).
All patients were women, median age was 53.5 years (range,
28–85), and 51.2% had elevated serum LDH (Table 1). The popu-
lation was heavily pretreated, with 82.9% having received neoad-
juvant/adjuvant chemotherapy, and 43.5% having received 3
previous lines of therapy for metastatic disease.
Antitumor activity
All patients were evaluable for efficacy. In the total population,
two patients had a CR and seven patients had a PR, for an ORR of
5.3% (95% CI, 2.7–9.9) (Table 2). In the PD-L1–positive
population, two patients had a CR and four patients had a PR, for
an ORR of 5.7% (95% CI, 2.4–12.2) (Table 2). In the PD-L1–
negative population, zero patients had a CR and three patients
had a PR, for an ORR of 4.7% (95% CI, 1.1–13.4) (Table 2). Four
patients, all with PD-L1–positive disease, had SD 24 weeks,
leading to DCRs of 7.6% (95% CI, 4.4–12.7) in the total, 9.5%
(95% CI, 5.1–16.8) in the PD-L1–positive, and 4.7% (95% CI,
1.1–13.4) in the PD-L1–negative populations (Table 2).
Examination of subgroups in the total population revealed that
although ORR was numerically higher in patients with normal
versus elevated LDH, <3 versus3 metastatic organ sites, lymph
node metastases-only versus other, and nonvisceral-only versus
visceral (with or without nonvisceral) disease, all confidence
intervals overlapped, except for subgroups based on lymph node
metastases (Figure 1A). There were no responses in patients with
liver metastases. At the time of data cut-off, 6/9 responders in the
total population (5/6 PD-L1–positive and 1/3 PD-L1–negative
patients) did not experience subsequent disease progression or
death. The median duration of response was not reached in the
total (1.2þ–21.5þmonths) or PD-L1–positive populations (6.3–
21.5þ months), and was 4.4 months (1.2þ–4.6) in the PD-L1–







Female 170 (100) 105 (100) 64 (100)
Age, years, median (range) 53.5 (28–85) 53.0 (30–85) 55.0 (28–80)
Postmenopausal 140 (82.4) 85 (81.0) 54 (84.4)
ECOG performance status
0 90 (52.9) 51 (48.6) 38 (59.4)
1 80 (47.1) 54 (51.4) 26 (40.6)
LDH concentration
<1  ULN 82 (48.2) 53 (50.5) 28 (43.8)
1  ULN to <2.5  ULN 85 (50.0) 50 (47.6) 35 (54.7)
2.5  ULN 2 (1.2) 1 (1.0) 1 (1.6)
Unknown 1 (0.6) 1 (1.0) 0 (0.0)
Sum of the size of target lesions,b mm, median (range) 51.0 (10–531) 56.0 (10–531) 44.0 (11–178)
No. of metastatic organ sites
1 46 (27.1) 29 (27.6) 17 (26.6)
2 68 (40.0) 40 (38.1) 27 (42.2)
3 56 (32.9) 36 (34.3) 20 (31.3)
Visceral 6 nonvisceral disease 125 (73.5) 74 (70.5) 50 (78.1)
Prior taxane and anthracycline therapy 163 (95.9) 102 (97.1) 60 (93.8)
Previous (neo)adjuvant therapy 141 (82.9) 86 (81.9) 54 (84.4)
No. of previous lines of therapy for recurrent/metastatic disease
1 53 (31.2) 37 (35.2) 16 (25.0)
2 43 (25.3) 26 (24.8) 16 (25.0)
3 31 (18.2) 20 (19.0) 11 (17.2)
4 22 (12.9) 10 (9.5) 12 (18.8)
5 21 (12.4) 12 (11.4) 9 (14.1)
Data are presented as n (%) unless otherwise noted.
aIncludes one patient with unknown PD-L1 status.
bDefined as the sum of the longest diameters of target lesions measurable by central radiology review.
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; ULN, upper limit of normal.
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negative population (Table 2). Overall, 75.0% and 62.5% of res-
ponders had response duration 6 months and 12 months, re-
spectively (Table 2). Best percentage change from baseline in
target lesion size for the 146 patients with 1 evaluable post-
baseline imaging assessment is shown in Figure 1B.
By data cut-off, 158 (92.9%) patients had disease progression
or died. Median PFS was 2.0 months (95% CI, 1.9–2.0), and the
estimated 6- and 12-month PFS rates were 14.9% and 8.1%, re-
spectively; similar PFS was observed despite PD-L1 expression
status (Table 2, Figure 1C). Overall, 136 (80.0%) patients had
died. Median OS was 9.0 months (95% CI, 7.6–11.2), and the 6-
and 12-month OS rates were 69.1% and 39.8%, respectively;
similar OS was observed despite PD-L1 expression status
(Table 2, Figure 1D).
Safety
All patients were evaluable for safety. One hundred and three
(60.6%) patients experienced1 treatment-related AE, including
22 (12.9%) with 1 grade 3 or 4 event. No AEs led to death.
Seven (4.1%) patients discontinued pembrolizumab because of
treatment-related AEs. The most common treatment-related AEs
were fatigue (20.6%) and nausea (11.2%) (Table 3). The only
treatment-related AEs of grade 3 or 4 severity that occurred in2
patients were diarrhea [N¼ 3 (1.8%)] and increased alanine ami-
notransferase [N¼ 2 (1.2%)].
Immune-mediated AEs, considered regardless of attribution to
treatment by the investigator, occurred in 33 (19.4%) patients.
The most common immune-mediated AEs were hypothyroidism
(11.8%) and hyperthyroidism (5.3%) (Table 3). The only
immune-mediated AEs of grade 3 or 4 severity were one case of
grade 4 type 1 diabetes mellitus and one case of grade 3
pneumonitis.
Discussion
Pembrolizumab monotherapy demonstrated antitumor activity
in a subset of patients with previously treated mTNBC. Although
the ORR of 5.3% is lower than single-agent chemotherapy in this
setting, pembrolizumab avoided common chemotherapy toxic-
ities and responses were quite durable. At database cut-off, the
Table 2. Antitumor activity assessed by RECIST v1.1 per independent central review in the total, PD-L1–positive, and PD-L1–negative efficacy populations






ORR, n (%) [95% CI] 9 (5.3) [2.7–9.9] 6 (5.7) [2.4–12.2] 3 (4.7) [1.1, 13.4]
DCRa, n (%) [95% CI] 13 (7.6) [4.4–12.7] 10 (9.5) [5.1–16.8] 3 (4.7) [1.1–13.4]
Best overall response, n (%)
Complete response 2 (1.2) 2 (1.9) 0 (0.0)
Partial response 7 (4.1) 4 (3.8) 3 (4.7)
Stable disease 34 (20.0) 21 (20.0) 12 (18.8)
Progressive disease 103 (60.6) 66 (62.9) 37 (57.8)
Not able to be evaluatedb 6 (3.5) 3 (2.9) 3 (4.7)
Not able to be assessedc 18 (10.6) 9 (8.6) 9 (14.1)
Time to response,d months, median (range) 3.9 (1.9–8.1) 3.1 (1.9–6.2) 3.9 (1.9–8.1)
Duration of response,d,e months, median (range) NR (1.2þ to 21.5þ) NR (6.3 to 21.5þ) 4.4 (1.2þ to 4.6)
Estimated rate of response duration 6 months,d,e, % 6 (75.0) 6 (100.0) 0 (NR)
Estimated rate of response duration 12 months,d,e % 3 (62.5) 3 (83.3) 0 (NR)
Progression-free survival events, n (%) 158 (92.9) 95 (90.5) 62 (96.9)
Progression-free survival, months, median (95% CI)e 2.0 (1.9–2.0) 2.0 (1.9–2.1) 1.9 (1.7–2.0)
Progression-free survival at 6 months, %e 14.9 14.3 16.4
Progression-free survival at 12 months, %e 8.1 8.7 7.3
Death, n (%) 136 (80.0) 82 (78.1) 53 (82.8)
Overall survival, months, median (95% CI)e 9.0 (7.6, 11.2) 8.8 (7.1, 11.2) 9.7 (6.2, 12.6)
Overall survival at 6 months, %e 69.1 71.1 65.4
Overall survival at 12 months, %e 39.8 39.0 40.2
Total population includes the one patient who had disease that was not evaluable for PD-L1 expression. ‘þ’ indicates there is no progressive disease by
the time of last disease assessment.
aDCR ¼ the proportion of patients with complete or partial response or stable disease for 24 weeks.
bPatients who had 1 postbaseline tumor assessment, none of which were evaluable.
cPatients who had no postbaseline tumor assessment because of death, withdrawal of consent, loss to follow-up, or start of new anticancer therapy.
dEvaluated in patients who had a complete or partial response (n¼ 9 for the total population, n¼ 6 for the PD-L1–positive population, n¼ 3 for the
PD-L1–negative population).
eEstimated using the Kaplan–Meier method.
NR, not reached; RECIST, Response Evaluation Criteria in Solid Tumors.
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0 5 10 15 20 25 30 35 40 45 50 55
ORR, % (95% CI)
Subgroup N ORR (95% CI)
Overall 170   5.3% (2.7-9.9)
<50 years 65   6.2% (2.0-15.2)
50 years 105   4.8% (1.8-10.9)
Age
0 90   5.6% (2.1-12.7)
1 80   5.0% (1.6-12.5)
No. previous lines of therapy
2 to 3 96   6.3% (2.6-13.2)
≥4 74   4.1% (0.9-11.7)
LDH concentration
<ULN 82
  2.3% (0.1-8.5)≥ULN 87
  8.5% (3.9-16.8)
Menopausal status
Premenopausal 30   6.7% (0.8-22.4)
Postmenopausal 140   5.0% (2.3-10.1)
No. of metastatic organ sites
<3 114   7.0% (3.4-13.4)
≥3 56   1.8% (0.0-10.3)
Liver metastases
Yes 46   0.0% (0.0-9.2)
No 124   7.3% (3.7-13.4)
Lymph node metastases only
Yes 18 27.8% (12.2-51.2)
No 152   2.6% (0.8-6.8)
Visceral disease
Visceral 125   2.4% (0.5-7.1)
Nonvisceral only 45 13.3% (5.9-26.6)
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Figure 1. Antitumor activity of pembrolizumab in the total population. (A) Objective response rate assessed by RECIST v1.1 per independent
central review in subgroups of the efficacy population (N¼ 170). Prespecified subgroups include age, menopausal status, previous lines of
therapy, and liver metastases; all other subgroups are exploratory. (B) Best change from baseline in target lesion size assessed by RECIST v1.1
per independent central review in patients with 1 evaluable post-baseline imaging assessment (N¼ 146). (C) Progression-free survival
assessed by RECIST v1.1 per independent central review in the efficacy population (N¼ 170). (D) Overall survival in the efficacy population
(N¼ 170). E. Time to response and response duration assessed by RECIST v1.1 per independent central review. CR, complete response; ECOG,
Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; ORR, objective response rate; OS, overall survival; PD, progressive disease;
PFS, progression-free survival; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; ULN, upper limit of normal.
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duration of response was not reached, and 75.0% and 62.5% of
responders had a response duration of 6 and 12 months,
respectively. These results are encouraging compared with the
typical duration of response (1–3 months) to standard chemo-
therapy in the mTNBC setting [11]. The DCR was 9.5% in the
PD-L1–positive population and 4.7% in the PD-L1–negative
population. Taken together, these data support the durable effect
of pembrolizumab in patients who achieved a response, and pos-
sibly signal a greater benefit in the subset of patients with PD-L1–
positive tumors.
The study population was heavily pretreated, with 82.9% hav-
ing received neoadjuvant/adjuvant therapy, and 43.5% having
received 3 previous lines of therapy for metastatic disease. The
response to pembrolizumab may have been attenuated due to the
heavily pretreated population studied. Data from cohort B of the
present trial evaluating the antitumor activity of pembrolizumab
as first-line therapy for patients with PD-L1–positive mTNBC
show an ORR of 21.4% (95% CI, 13.9%–31.4%) [12], suggesting
an improved response with earlier line of treatment.
Pembrolizumab demonstrated a numerically lower ORR in
patients with poor prognostic factors, including elevated LDH, a
greater number of metastatic sites, and visceral disease. No
responses were observed in patients with liver metastases.
Previous studies in patients with melanoma and non-small-cell
lung cancer have also shown reduced response to immunothera-
pies with liver metastases, coinciding with reduced antigen-
specific T-cell infiltration [13]. Patients with poor prognostic fac-
tors should be considered for alternative strategies, including
combination of immune checkpoint inhibitors with cytotoxic
agents.
These results supplement findings from smaller trials of pem-
brolizumab and other immune checkpoint inhibitors for the
treatment of TNBC. In the phase Ib KEYNOTE-012 trial of pem-
brolizumab as first line or greater treatment for patients with
mTNBC selected by PD-L1 expression (N¼ 32), ORR was 18.5%
in 27 evaluable patients [9]. In a phase Ib study of avelumab in
patients with metastatic breast cancer (N¼ 168), the confirmed
ORR was 5.2% in patients with TNBC (N¼ 58), with higher
ORR in PD-L1–positive versus PD-L1–negative TNBC (22.2%
versus 2.6%) [14]. Single-agent atezolizumab in patients with
mTNBC (N¼ 116) produced an ORR of 10% in the overall
population, which was higher in first-line (N¼ 21; 24%) versus
second-line or greater treatment (N¼ 94; 6%) [15]. In addition
to monotherapy studies, combinations of different immune
checkpoint inhibitors and immune checkpoint inhibition with
chemotherapy for TNBC are being evaluated, and preliminary
data suggest increased response rates with the combinations ver-
sus their respective single-agent components [16–18].
Pembrolizumab demonstrated an acceptable safety profile.
Treatment-related AEs were common; however, the incidence of
grade 3 or 4 treatment-related AEs was low and similar to earlier
anti-PD-L1/PD-1 monotherapy studies for the treatment of
breast cancer [9, 15]. Few patients discontinued due to
treatment-related AEs, and no deaths due to AEs were reported.
This study had several limitations. The small number of res-
ponders precludes definitive identification of patient subgroups
with mTNBC who would most likely derive clinical benefit from
pembrolizumab. Additionally, the modest response to pembroli-
zumab in this heavily pretreated population is not generalizable
to patients with less advanced disease. Indeed, available results
with pembrolizumab in the first-line setting demonstrate a higher
ORR than that observed here [12], and studies of pembrolizumab
as monotherapy and in combination with chemotherapy are on-
going in less heavily treated or previously untreated mTNBC, and
in the neoadjuvant and adjuvant settings. Finally, the use of PD-
L1 as a predictive biomarker to compare results across studies of
different immunotherapies is limited by differences in detection
antibodies and IHC cut-offs [19]. Additional studies of immune
biomarkers to identify patients most likely to benefit from immu-
notherapies are critical. Early findings from the present study
suggest that tumor infiltrating lymphocyte (TIL) levels can iden-
tify patients with mTNBC who have a greater chance of achieving
response to pembrolizumab monotherapy [20].
In conclusion, pembrolizumab monotherapy showed durable
antitumor activity in a small subset of patients with heavily pre-
treated mTNBC and had a manageable safety profile, with most
AEs of low grade. Survival was promising, particularly in patients
with CR, PR, or SD. Whereas clinical features (normal LDH, ab-
sence of liver metastases, etc.) and the presence of TILs can enrich
for a TNBC population with higher response rate, further eluci-
dation of the molecular or immunologic features of responders
may identify a subset of patients who have excellent outcomes
with pembrolizumab monotherapy. Randomized studies of pem-
brolizumab monotherapy and pembrolizumab-based combin-
ation therapy for the treatment of TNBC are ongoing.
Table 3. Adverse events in the total treated population (N 5 170)
Adverse event Any grade Grade 3–4
Treatment related, incidence 5%
Any 103 (60.6) 22 (12.9)
Fatigue 35 (20.6) 1 (0.6)
Nausea 19 (11.2) 1 (0.6)
Hypothyroidism 14 (8.2) 0
Decreased appetite 13 (7.6) 0
Diarrhea 12 (7.1) 3 (1.8)
Asthenia 11 (6.5) 0
Pruritus 11 (6.5) 0
Arthralgia 10 (5.9) 0
Hyperthyroidism 9 (5.3) 0
Immune mediated, incidence >0%
Hypothyroidism 20 (11.8) 0
Hyperthyroidism 9 (5.3) 0
Pneumonitis 7 (4.1) 1 (0.6)
Infusion-related reaction 3 (1.8) 0
Colitis 2 (1.2) 0
Myocarditis 1 (0.6) 0
Type 1 diabetes mellitus 1 (0.6) 1 (0.6)
Data are presented as n (%), where n is the number of patients who
experienced 1 episode of a given event. Relatedness to treatment was
determined by the investigator. Immune-mediated events were based
on a list of terms specified by the sponsor and considered regardless of
attribution to treatment or immune relatedness by the investigator;
related terms were included.
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